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Background: Sudden cardiac death (SCD) is a major cause of mortality worldwide. The benefits of automatic implantable cardioverter/
defibrillators (AICD) are well established in certain patient populations. Unfortunately, not all patients at risk for SCD meet guidelines for AICD 
implantation and how to protect them is unclear. In 2004, two studies were completed (WEARIT/BIROAD) that proved external wearable defibrillators 
(WD) to be effective in terminating potentially lethal cardiac tachyarrhythmia in high-risk patients who did not meet specific guideline criteria for 
implantation of AICD.
Methods: This is a retrospective, outcomes study conducted as a chart review of hospital and office records of patients prescribed a WD from 
2006 to 2009. We collected age, gender, reason for use, compliance with use, adverse reactions, therapies delivered, and overall outcomes.
Results: Of 158 WD patients, 104 patients had a WD prescribed for newly discovered cardiomyopathy (NDCM). Etiologies were ischemic in 47 
patients and non-ischemic in 56. There were 3 appropriate (2 for ventricular tachycardia and 1 for ventricular fibrillation) and 1 inappropriate 
shocks delivered to NDCM patients. The inappropriate shock was delivered due to ECG signal artifact. In the 158 WD patients, 3 patients died from 
non-arrhythmic causes (2 patients with end stage congestive heart failure and 1 patient who experienced an acute myocardial infarction associated 
with septic shock). No patients in this study died from a primary arrhythmic event while using the wearable defibrillator.
Conclusions: Based on this study, the wearable defibrillator appears to be a safe and effective device for aborting SCD due to lethal 
tachyarrhythmias when used as a protective bridge in patients with an unclear need for AICD implantation.
